2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy
Novartis Joined By Roche, Novo Nordisk For Highest BD Spending
Nine biopharma companies made 12 or more deals, with Novartis inking 21 deals and leading M&A activity. Roche, meanwhile, spent little up front but maintained a hectic pace with 12 alliances.
